Analytical Data
-
Gene name
IL-27R alpha/TCCR
- Application
-
Alternative Names
CRL1; IL27R; TCCR; WSX1; Zcytor1; T-Cell Cytokine Receptor Type 1; Cytokine receptor-like 1; Type I T-cell cytokine receptor
-
Species
Rat
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
D4A6K5
-
Expression Region
Thr93~Gln273
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL-27R alpha, also known as TCCR (IL-27 receptor alpha), is a key component of the interleukin-27 (IL-27) signaling pathway, which plays a critical role in immune regulation and inflammation. IL-27 is a member of the IL-6 cytokine family, produced primarily by dendritic cells and macrophages, and is known for its ability to influence the differentiation and function of various immune cells, including T cells and B cells. The IL-27R alpha chain is responsible for binding to IL-27, initiating downstream signaling that can modulate immune responses, promote the development of regulatory T cells, and enhance the antiviral and antitumor activities of immune cells. Research into the IL-27R alpha/TCCR recombinant protein has gained momentum due to its potential therapeutic applications in autoimmune diseases, cancer, and chronic inflammatory conditions. By understanding the structural and functional properties of this receptor, scientists aim to develop innovative treatments that can either enhance or inhibit its signaling pathways, thus manipulating immune responses for clinical benefit. Furthermore, the recombinant protein serves as a valuable tool for studying IL-27 signaling mechanisms and identifying biomarkers for diseases influenced by this pathway, paving the way for novel therapeutic interventions in the field of immunology and oncology.
